# Radiopharm Theranostics Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Radiopharm Theranostics Ltd). ## Overview Radiopharm Theranostics Ltd is an Australia-based clinical-stage radiopharmaceutical company developing diagnostic and therapeutic products for cancer. Its pipeline spans peptides, small molecules, and monoclonal antibodies designed to target solid tumors across multiple indications. ## Products & services • Clinical-stage radiopharmaceutical diagnostics and therapeutics • Peptide-based oncology programs • Small-molecule imaging and therapeutic candidates • Monoclonal antibody-based radiopharmaceuticals • Solid-tumor clinical development programs - **Radiopharmaceutical therapeutics** (40%) — Cancer-targeted radioactive drug candidates intended to treat tumors. - **Diagnostic imaging agents** (25%) — Radiolabeled agents used to visualize and characterize tumors. - **Peptide programs** (15%) — Peptide-based assets used in targeted oncology imaging and therapy. - **Small-molecule programs** (10%) — Small-molecule radiopharmaceutical candidates such as RAD 101. - **Monoclonal antibody programs** (10%) — Antibody-based radiopharmaceutical assets for targeted cancer applications. - Clinical-stage radiopharmaceutical diagnostics and therapeutics - Peptide-based oncology programs - Small-molecule imaging and therapeutic candidates - Monoclonal antibody-based radiopharmaceuticals - Solid-tumor clinical development programs ## Customers Radiopharm’s customers are primarily oncology researchers, clinical trial sites, and eventual hospital and specialist physician users of approved diagnostic or therapeutic agents. In the current development stage, value is created through clinical data generation, trial enrollment, and partnering rather than broad commercial sales. The relevant end markets are patients with solid tumors, especially in lung, breast, prostate, and brain cancers. - **Clinical trial sites** (primary) — Hospitals and research centers that enroll patients and generate data for the pipeline. - **Oncology clinicians** (primary) — Specialist physicians and cancer centers that would use approved imaging or therapy products. - **Strategic partners** (secondary) — Biopharma partners that may license or co-develop radiopharmaceutical assets. - **Patients with solid tumors** (primary) — Patients in lung, breast, prostate, brain and other solid tumor indications targeted by the pipeline. - Clinical trial investigators running oncology studies - Hospitals and cancer centers treating solid tumors - Specialist physicians using targeted imaging or therapy - Pharmaceutical partners evaluating licensing opportunities - Patients with hard-to-treat solid tumors ## Geography The company is incorporated and headquartered in Australia, with principal offices in Carlton, Victoria, and it also has a U.S. market presence through NASDAQ listing and investor relations activity. Its clinical programs are global in scope, but the business is operationally centered in Australia and the United States. Geography matters because clinical development, capital access, and future commercialization will depend on regulatory and trial execution across multiple jurisdictions. - Headquartered and incorporated in Australia - Principal place of business in Carlton, Victoria - Listed on ASX and NASDAQ - Clinical development has international trial exposure - U.S. capital markets are an important funding venue ## Strategy Radiopharm’s strategy is to advance a differentiated pipeline of radiopharmaceutical assets through clinical milestones and expand the evidence base for partnering or later-stage development. A key priority is progressing multiple programs across peptides, small molecules, and antibodies so the company is not dependent on a single asset. The company also emphasizes strategic partnering and external funding to support development across its oncology pipeline. - **Advance clinical milestones** (short-term) — Clinical data is the main value driver for a radiopharmaceutical developer. - **Broaden the pipeline** (medium-term) — Multiple modalities reduce single-asset dependence and improve partnering optionality. - **Secure strategic partnering** (medium-term) — Partnerships can fund development and validate asset quality. - Advance RAD 101 and other clinical programs - Move multiple assets through Phase 1 and Phase 2 trials - Build differentiated radiopharmaceutical platform coverage - Pursue strategic partnering for non-dilutive value creation - Use capital markets to fund clinical development ## Risks As a clinical-stage biopharma company, Radiopharm faces substantial execution risk because value depends on trial enrollment, clinical outcomes, and regulatory progress. It also relies on external financing and partner interest to fund ongoing development, which makes capital access and dilution important business risks. More broadly, radiopharmaceutical development carries scientific, manufacturing, and safety risks, particularly for novel oncology assets. - **Clinical development failure** [high] — Pipeline value depends on positive data from Phase 1 and Phase 2 studies. - **Funding and dilution risk** [high] — The business is pre-commercial and needs external capital to finance trials. - **Regulatory and trial execution risk** [high] — Approvals, site activation, and enrollment affect timing and outcomes. - **Manufacturing and radioisotope complexity** [medium] — Radiopharmaceutical products require specialized production, logistics, and safety controls. - Clinical trial failure could materially reduce asset value - Regulatory delays can slow development and partnering - Capital needs may require ongoing equity funding - Radiopharmaceutical handling and manufacturing are complex - Safety or efficacy concerns can end programs early ## Accounting Investors should focus on revenue recognition for any customer contracts, since the company is still early in commercialization and revenue can be lumpy. Research and development spend, clinical trial costs, and any capitalized development or intangible asset balances will strongly affect reported results, while going-concern judgments can influence the interpretation of the financial statements. As a clinical-stage biotech, fair value estimates, impairment assessments, and share-based payment accounting are also likely to be important. - **Revenue recognition** — Can make revenue uneven and hard to compare period to period - **Research and development expense** — Drives reported losses and cash burn - **Going concern** — Important for assessing financing risk and continuity - **Fair value and impairment** — Can materially affect reported assets and earnings - Revenue recognition depends on limited customer contract activity - R&D expense captures most clinical development spend - Going-concern assessment remains material for investors - Impairment and valuation judgments can affect asset values - Share-based payment accounting can be a meaningful non-cash item --- *Last updated: 2026-09-28T12:13:49.443298+00:00*